Effects of Alcohol Reduction or Cessation on Cancer Risk
Evidence indicates lower risks of oral and esophageal cancers when people reduce or cease alcohol use, according to a Special Report from a working group
Evidence indicates lower risks of oral and esophageal cancers when people reduce or cease alcohol use, according to a Special Report from a working group
In an interim analysis of the phase 3 KEYNOTE-811 trial, pembrolizumab with first-line trastuzumab and chemotherapy significantly improved progression-free survival in patients with locally advanced
Compared with standard care in 160 patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C, sotorasib plus panitumumab increased progression-free survival, researchers report, with only expected
Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody–drug conjugate targeting folate receptor α (FRα), showed benefits in phase 3 trial participants with platinum-resistant, FRα-positive ovarian cancer. Compared with
Used with first-line chemotherapy in patients with unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, sintilimab significantly improved overall survival compared with placebo,
At an age-adjusted life-year (QALY) threshold of $200,000 per quality-adjusted life-year (QALY), neither second-line axicabtagene ciloleucel (axi-cel) nor lisocabtagene maraleucel (liso-cel) was cost-effective in patients
In the phase 3 IMerge trial, patients with lower-risk myelodysplastic syndromes (LR-MDS) who were not responding to or were ineligible for erythropoiesis-stimulating agents (ESAs) had
Clinical findings from the JUPITER-02 trial support the use of toripalimab plus gemcitabine-cisplatin as the new standard of care for first-line treatment of patients with
In patients with metastatic urothelial carcinoma and FGFR alterations after previous immune checkpoint treatment, the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib significantly increased overall survival, compared
Point-of-sale prices for generic imatinib are substantially higher than the pharmacy acquisition costs from 2017 to 2023, a study of Medicare Part D beneficiaries shows.